Latest data demonstrate sustained results of Bydureon® treatment over six years with a second, retrospective study showing a higher likelihood of adherence with exenatide once-weekly vs. other GLP-1 therapies in type 2 diabetes patients (AstraZeneca)
Diabetes News Service
Glycosmedia is also available as an App:
For iPhone and iPad | For Android devices
Sponsorship and Advertising
For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com
